These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22475391)

  • 1. Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease.
    Reese JP; Dams J; Winter Y; Balzer-Geldsetzer M; Oertel WH; Dodel R
    Expert Opin Pharmacother; 2012 May; 13(7):939-58. PubMed ID: 22475391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
    Talati R; Reinhart K; Baker W; White CM; Coleman CI
    Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of the pharmacoeconomics of Parkinson disease medications.
    Wang AS; Gunzler SA
    Expert Opin Pharmacother; 2019 Sep; 20(13):1659-1670. PubMed ID: 31150294
    [No Abstract]   [Full Text] [Related]  

  • 7. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced strategies for treatment of Parkinson's disease: the role of early treatment.
    Jann MW
    Am J Manag Care; 2011 Oct; 17 Suppl 12():S315-21. PubMed ID: 22087552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
    Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
    Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the direct and indirect costs associated with Parkinson's disease.
    Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature.
    Becerra JE; Zorro O; Ruiz-Gaviria R; Castañeda-Cardona C; Otálora-Esteban M; Henao S; Navarrete S; Acevedo JC; Rosselli D
    World Neurosurg; 2016 Sep; 93():44-9. PubMed ID: 27216925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early pharmacologic treatment in Parkinson's disease.
    Hauser RA
    Am J Manag Care; 2010 Mar; 16 Suppl Implications():S100-7. PubMed ID: 20297870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing prodrugs for the treatment of Parkinson's disease.
    Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
    Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the pharmacologic management of early Parkinson disease.
    Hauser RA; Zesiewicz TA
    Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabergoline versus levodopa monotherapy: a decision analysis.
    Smala AM; Spottke EA; Machat O; Siebert U; Meyer D; Köhne-Volland R; Reuther M; DuChane J; Oertel WH; Berger KB; Dodel RC
    Mov Disord; 2003 Aug; 18(8):898-905. PubMed ID: 12889079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: diagnosis and treatment.
    Rao SS; Hofmann LA; Shakil A
    Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.